Q1 2025 Management View CEO Linda Marban reviewed progress on the Biologics License Application (BLA) for deramiocel, targeting full approval for treating Duchenne muscular dystrophy (DMD) ...

Daré will host a conference call and live webcast today, May 13, 2025, at 4:30 p.m. Eastern Time to review financial results ...

The FDA will issue a decision on the BLA for RGX-121 by November, which if positive, could make it the first gene therapy for Hunter syndrome.

Welcome to FibroGen first quarter 2025 earnings conference call. (Operator Instructions). Please be advised today's conference is being recorded. I would not like to end the conference over to your ...

Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now esti ...

Mineralys Therapeutics reports strong Q1 2025 results, announcing pivotal trial success for lorundrostat, a $201M equity raise, and progress toward ...

Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ETCompany ParticipantsZack Armen - Head of Investor RelationsGaro Armen ...

Recently, underscoring a commitment to national security, the White House and the Food and Drug Administration (FDA) issued separate ...

The Food and Drug Administration is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, ...

The weight-loss drug revolution is reshaping the health and wellness industry, forcing companies to adapt or face the same ...

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.